Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
Associated Therapies
-

Warfarin Patient Self-Monitoring

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2009-06-19
Last Posted Date
2010-03-08
Lead Sponsor
University of British Columbia
Target Recruit Count
25
Registration Number
NCT00925028
Locations
🇨🇦

Gaetz Family Practice, Chilliwack, British Columbia, Canada

The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

First Posted Date
2009-06-05
Last Posted Date
2011-06-01
Lead Sponsor
Pfizer
Target Recruit Count
14
Registration Number
NCT00914667
Locations
🇺🇸

Pfizer Investigational Site, New Haven, Connecticut, United States

Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects

First Posted Date
2009-05-19
Last Posted Date
2016-10-17
Lead Sponsor
AstraZeneca
Target Recruit Count
30
Registration Number
NCT00904176
Locations
🇺🇸

Pra International, Lenexa, Kansas, United States

A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects

Phase 1
Completed
Conditions
First Posted Date
2009-03-05
Last Posted Date
2013-07-02
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
24
Registration Number
NCT00856570

A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

First Posted Date
2009-01-22
Last Posted Date
2018-10-16
Lead Sponsor
Pfizer
Target Recruit Count
14
Registration Number
NCT00827034
Locations
🇺🇸

Pfizer Investigational Site, New Haven, Connecticut, United States

Prothrombin Times Outside the Therapeutic Range in Otherwise Stable Patients

First Posted Date
2008-12-24
Last Posted Date
2012-08-01
Lead Sponsor
Hamilton Health Sciences Corporation
Target Recruit Count
160
Registration Number
NCT00814177
Locations
🇨🇦

Thrombosis Service, HHS-General Hospital, Hamilton, Ontario, Canada

A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation

Phase 2
Completed
Conditions
Interventions
First Posted Date
2008-11-07
Last Posted Date
2013-05-01
Lead Sponsor
Pfizer
Target Recruit Count
222
Registration Number
NCT00787150
Locations
🇯🇵

Pfizer Investigational Site, Kumamoto, Japan

Drug Interaction Study of Rifampin and Warfarin in Healthy Volunteers.

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2008-10-22
Last Posted Date
2013-07-17
Lead Sponsor
University of California, San Francisco
Target Recruit Count
10
Registration Number
NCT00777855
Locations
🇺🇸

UCSF Medical Center, San Francisco, California, United States

Prophylaxis Against DVTs After Primary Hip and Knee Replacement Surgery

Not Applicable
Conditions
Interventions
First Posted Date
2008-10-07
Last Posted Date
2011-09-26
Lead Sponsor
The New England Baptist Hospital
Target Recruit Count
330
Registration Number
NCT00767559
Locations
🇺🇸

New England Baptist Hospital, Boston, Massachusetts, United States

Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin

Phase 2
Completed
Conditions
Interventions
First Posted Date
2008-08-28
Last Posted Date
2023-08-07
Lead Sponsor
Portola Pharmaceuticals
Target Recruit Count
508
Registration Number
NCT00742859
Locations
🇨🇦

Portola Investigational Site, Montreal, Quebec, Canada

© Copyright 2024. All Rights Reserved by MedPath